Sirona, WuXi to Manufacture Anti-Aging/Anti-Wrinkle Compound for Clinical Trial

  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec (“WuXi”), Shanghai, for the small-scale production of TFC-1326, a powerful active against the aging effects on skin.

Years of groundbreaking research by Sirona’s team of scientists at TFChem has shown in preclinical studies that TFC-1326 has the potential to reverse the effects of aging on skin, including the potential to eliminate fine wrinkles. The scientific data is strong, and we are now preparing for a clinical trial. There are no existing compounds that our scientists are aware of, that have the potential to reverse the effects of the aging process on skin to truly restore its structure and youthful appearance. The anti-aging and anti-wrinkle markets are estimated to be $271 Billion USD globally by 2024.

https://www.globenewswire.com/news-release/2022/06/22/2466770/0/en/Sirona-Biochem-Contracts-WuXi-AppTec-to-Manufacture-Revolutionary-Anti-Aging-Anti-Wrinkle-Compound-for-Clinical-Trial.html